Get the Stockscreener App
8.625
1.09%
-0.095
Biocryst Pharmaceuticals Inc stock is traded at $8.625, with a volume of 1.08M.
It is down -1.09% in the last 24 hours and down -16.18% over the past month.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
See More
Previous Close:
$8.72
Open:
$8.75
24h Volume:
1.08M
Relative Volume:
0.24
Market Cap:
$1.80B
Revenue:
$503.49M
Net Income/Loss:
$-53.47M
P/E Ratio:
-33.17
EPS:
-0.26
Net Cash Flow:
$-26.89M
1W Performance:
-4.80%
1M Performance:
-16.18%
6M Performance:
+22.17%
1Y Performance:
+13.04%
1-Day Range:
$8.58
$8.80
1-Week Range:
$8.58
$9.07
52-Week Range:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Name
Biocryst Pharmaceuticals Inc
Sector
Phone
919-859-1302
Address
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.625 | 1.84B | 503.49M | -53.47M | -26.89M | -0.26 |
|
ZTS
Zoetis Inc
|
151.09 | 70.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.64 | 47.44B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.685 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.85 | 19.07B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.01 | 13.28B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-25 | Initiated | Wedbush | Outperform |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Sep-18-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Aug-04-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-13-23 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-22-23 | Upgrade | Needham | Hold → Buy |
| Nov-02-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-05-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-05-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-18-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Aug-06-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-03-21 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Sep-29-20 | Resumed | JP Morgan | Overweight |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| May-05-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-15-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| May-24-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-16-18 | Resumed | Piper Jaffray | Overweight |
| Aug-08-18 | Resumed | JP Morgan | Overweight |
| Jul-17-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jun-22-18 | Initiated | Seaport Global Securities | Neutral |
| Jan-02-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-20-17 | Initiated | Barclays | Equal Weight |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-06-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-06-17 | Upgrade | Jefferies | Hold → Buy |
| Feb-16-17 | Initiated | Ladenburg Thalmann | Buy |
| Aug-12-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-04-16 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-09-16 | Reiterated | FBR Capital | Outperform |
| Feb-09-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-09-16 | Downgrade | Needham | Buy → Hold |
View All
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
AscellaHealth’s Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies - GlobeNewswire Inc.
Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB - The Globe and Mail
RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 - Yahoo Finance
BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit - GlobeNewswire
Island Pharmaceuticals announces purchase of Galidesivir antiviral program from Biocryst Pharmaceuticals - MarketScreener
BioCryst appoints Babar Ghias as CFO - MSN
Island Pharmaceuticals acquires BioCryst’s Galidesivir - grafa.com
BioCryst Pharmaceuticals appoints Babar Ghias as CFO By Investing.com - Investing.com South Africa
BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development - GlobeNewswire
CFO changes at Biocryst, Xenon, Century, Pyxis - biocentury.com
Missed PDUFA history as Kalvista wins FDA approval for HAE - BioWorld MedTech
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? - Yahoo
BioCryst Pharmaceuticals (BCRX) Appoints New CFO, Babar Ghias - GuruFocus
BioCryst Pharmaceuticals Appoints Babar Ghias as Chief Financial Officer and Head of Corporate Development - Quiver Quantitative
BioCryst Pharmaceuticals appoints Babar Ghias as CFO - Investing.com
BioCryst Taps Dealmaking Powerhouse as New CFO: $80B Transaction Expert to Drive Growth Strategy - Stock Titan
BioCryst Appoints Babar Ghias Chief Financial Officer and Head o - GuruFocus
BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M - Insider Monkey
10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Expands Team with 57,000 Share RSU Package: Latest Details on New Hiring Spree - Stock Titan
BioCryst Pharma (BCRX) Receives Boost with Increased Price Target | BCRX Stock News - GuruFocus
BioCryst Sells BioCryst Ireland to Neopharmed Gentili - TipRanks
Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound - insights.citeline.com
BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Nasdaq
Strategic Patience Pays Off: Biocryst's ORLADEYO Pediatric NDA Delay and Its Path to Long-Term Growth - AInvest
Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? - Nasdaq
BioCryst Stockholders Approve Stock Incentive Plan Amendment - TipRanks
BioCryst reports long-term efficacy of ORLADEYO in HAE treatment By Investing.com - Investing.com South Africa
Orladeyo approved in Colombia to prevent HAE swelling attacks - Angioedema News
BioCryst reports long-term efficacy of ORLADEYO in HAE treatment - Investing.com Australia
BioCryst (BCRX) Showcases Promising Results for ORLADEYO in HAE Treatment | BCRX Stock News - GuruFocus
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI | BCRX Stock News - GuruFocus
BioCryst Presents New Data on the Long-term Efficacy and - GlobeNewswire
ORLADEYO Clinical Trial Results: 86% Attack Reduction Transforms Life for HAE Patients of All Ages - Stock Titan
Sector Update: Health Care Stocks Lean Lower Premarket Friday - MarketScreener
BioCryst Pharmaceuticals, Inc. Announces National Institute of Drug and Food Surveillance Grants Approval for Oral, Once-Daily ORLADEYO - marketscreener.com
Colombia approves BioCryst’s oral HAE treatment ORLADEYO By Investing.com - Investing.com Canada
BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Preventio - GuruFocus
BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia - marketscreener.com
BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Prevention | BCRX Stock News - GuruFocus
ORLADEYO® (berotralstat) Approved in Colombia | BCRX Stock News - GuruFocus
ORLADEYO® (berotralstat) Approved in Colombia - GlobeNewswire
FDA-Approved ORLADEYO Expands to Colombia, Marking 6th Latin American Market for HAE Treatment - Stock Titan
Orladeyo approved for reimbursement in the Netherlands - Angioedema News
Marburg Virus Disease Pipeline 2025: Therapies Under - openPR.com
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Analysis: A 46.47% Upside Potential Amidst Strong Revenue Growth - DirectorsTalk Interviews
BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability By Investing.com - Investing.com Nigeria
BioCryst at Goldman Sachs Conference: Strategic Growth and Profitability - Investing.com Australia
Transcript : BioCryst Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
California State Teachers Retirement System Boosts Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
Biocryst Pharmaceuticals Inc Stock (BCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
7.87%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):